Dosimetric comparison between interstitial brachytherapy and volumetric-modulated arc therapy for tumor bed boost in breast cancer

乳腺癌肿瘤床强化治疗中组织间近距离放射治疗与容积调强弧形放射治疗的剂量学比较

阅读:1

Abstract

PURPOSE: To dosimetrically compare high-dose-rate interstitial brachytherapy (HDR-BT) with volumetric-modulated arc therapy (VMAT) for tumor bed boost, following breast conservative treatment. MATERIAL AND METHODS: 50 patients with early-stage breast cancer who underwent breast conservation surgery, followed by either HDR-BT (n = 25) of 15 Gy in 6 fractions over a period of 3 days, or VMAT dose of 16 Gy in 8 fractions (n = 25) for tumor bed boost, were retrospectively reviewed. All patients received whole breast irradiation of 46 Gy in 23 fractions. Dosimetric parameters for organs at risk (OARs), including ipsilateral and contralateral lungs, heart, contralateral breast, skin, and ribs, were evaluated with the help of dose-volume histograms (DVH). RESULTS: Heart sparing was similar in both modalities (left-sided breast irradiation, HDR-BT D(2cc) 20.5% vs. VMAT 30.2%, p-value = 0.243; right-sided breast irradiation, D(2cc) 6.5% vs. 4.4%, p-value = 0.165). Left-sided cases received higher dose to heart compared to right-sided patients. Interstitial brachytherapy resulted in significantly less dose to contralateral breast (D(2cc) 4.3% vs. 9.6%, p-value < 0.0001), ipsilateral lung (D(2cc) 27.6% vs. 73.2%, p-value < 0.0001), contralateral lung (D(2cc) 4.2% vs. 14.5%, p-value < 0.0001), ribs (D(2cc) 24.1% vs. 41.2%, p-value < 0.0001), and skin (D(2cc) 77.3% vs. 95%, p-value < 0.0001). CONCLUSIONS: HDR-BT-based tumor bed boost irradiation results in significantly lower doses to most organs at risk with similar heart sparing compared to VMAT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。